Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program

Media Center PRESS RELEASE 2014 ELUSYS ANNOUNCES RESULTS FROM THREE PHASE 3 SAFETY STUDIES OF ITS ANTHRAX ANTI-TOXIN, OBILTOXAXIMAB (ETI-204), IN ADULT VOLUNTEERS AND COMPLETION OF ITS PHASE 3 CLINICAL DEVELOPMENT PROGRAM PINE BROOK, NJ, September 22, 2014 – Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, today announced […]

Elusys Completes Commercial Manufacturing Process Validation for Anthrax Antitoxin ETI-204

Media Center PRESS RELEASE 2014 Elusys Completes Commercial Manufacturing Process Validation for Anthrax Antitoxin ETI-204, Appoints Larry Gyenes, Formerly of Columbia Laboratories, as Chief Financial Officer PINE BROOK, NJ, April 8, 2014 – Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, today announced that it has completed validation of the […]

Elusys Receives Notice of Allowance from U.S. Patent Office for Methods of Preventing or Treating Anthrax with ETI-204, an Anti-Anthrax Antibody, via Intramuscular Injection

Media Center PRESS RELEASE 2014 Elusys Receives Notice of Allowance from U.S. Patent Office for Methods of Preventing or Treating Anthrax with ETI-204, an Anti-Anthrax Antibody, via Intramuscular Injection PINE BROOK, NJ, March 10, 2014 – Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, announced that the United States […]

Elusys Completes Enrollment In Three Phase 3 Safety Studies Of Its Anthrax Anti-toxin, ETI-204, In Adult Volunteers

Media Center PRESS RELEASE 2014 ELUSYS COMPLETES ENROLLMENT IN THREE PHASE 3 SAFETY STUDIES OF ITS ANTHRAX ANTI-TOXIN, ETI-204, IN ADULT VOLUNTEERS Over 400 subjects participating in phase 3 studies PINE BROOK, NJ, February 5, 2014 – Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, today announced it has […]

Elusys Reports Its Anti-toxin Achieved 100% Survival Rate Following Anthrax Challenge In Pre-treatment Animal Study

Media Center PRESS RELEASE 2014 ELUSYS REPORTS ITS ANTI-TOXIN ACHIEVED 100% SURVIVAL RATE FOLLOWING ANTHRAX CHALLENGE IN PRE-TREATMENT ANIMAL STUDY Company presents data from four research studies at ASM Biodefense conference PINE BROOK, NJ, January 30, 2014 – Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, presented data demonstrating that […]